Please login to the form below

Not currently logged in
Email:
Password:

France withdraws Takeda diabetes drug

France and Germany have suspended the use of Takeda’s diabetes drug Actos after concerns that they could increase the risk of bladder cancer

France and Germany have suspended the use of Takeda's diabetes drug Actos after concerns that the drug could increase the risk of bladder cancer.

The Agence française de sécurité sanitaire des produits de santé (Afssps) has suspended the use of Actos (pioglitazone) and Competact (pioglitazone and metformin) until a European safety review has been concluded.

Afssps took the decision after a French study of public insurance data confirmed a slight increase in the risk of bladder cancer in patients treated with pioglitazone.

It said the suspension would take effect from next month in order for patients who are currently using either of the medications to switch to new ones. It estimated 230,000 patients in France were currently using one of the medications.

A Takeda spokeswoman told the Wall Street Journal: "We're working swiftly to deal with the orders raised by the French and German drug safety authorities."

The EMA's Committee for Medicinal Products for Human Use (CHMP) started a European review of pioglitazone-containing medicines in March 2011 to investigate the signal of a possible increased risk of bladder cancer with pioglitazone.

The CHMP is currently reviewing all relevant data, including data from pharmacoepidemiological studies, non-clinical and clinical data, post-marketing reports of bladder cancer and published data to assess their impact on the balance of benefits and risks of these medicines. The committee will now also assess the results of the French study and its potential impact on the use of these medicines across the whole EU. The CHMP will discuss this issue at their next meeting on 20-23 June 2011 and recommend appropriate actions as necessary.

While this review is ongoing the CHMP is not recommending any changes to the use of pioglitazone-containing medicines.

Actos, which is typically used to treat type-2 diabetes, has annual 2010 sales of Y387.9 billion ($4.83 billion).

13th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...